# GABAergic Modulation in Pain Transmission in Human: Effect of the GABAA Agonist Clobazam on Peripheral and Central Sensitisation

> **NCT01291316** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Hospital, Geneva** · enrollment: 25 (actual)

## Conditions studied

- Neuropathic Pain

## Interventions

- **DRUG:** Clonazepam
- **DRUG:** Tolterodine
- **DRUG:** clobazam

## Key facts

- **NCT ID:** NCT01291316
- **Lead sponsor:** University Hospital, Geneva
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2011-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01291316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01291316, "GABAergic Modulation in Pain Transmission in Human: Effect of the GABAA Agonist Clobazam on Peripheral and Central Sensitisation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01291316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*